Segmentation of Structural Abnormalities in Chronic Lung Diseases

Asthma Clinical Trial

— NOVAA  

Official title:

Segmentation of Structural Abnormalities in Chronic Lung Diseases

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04760548
• Other study ID #: NOVAA
• Status: Active, not recruiting
• Start date: January 1, 2008
• Est. completion date: February 17, 2024

Study information

• Verified date: September 2023
• Source: Hôpital Haut-Lévêque
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lung structural abnormalities are complex, time-consuming, and may lack reproducibility to evaluate visually on CT scans. The study's aim is to perform automated recognition of structural abnormalities in CT scans of patients with chronic lung diseases by using dedicated software.

Description:

Three chronic lung diseases will constitute the target of the study, by using retrospective data from each lung disease:

• Cystic fibrosis

• Asthma and COPD

• Interstitial lung diseases

Dedicated algorithms will be developped for each disease condition.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 800
• Est. completion date: February 17, 2024
• Est. primary completion date: February 17, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with chronic lung disease and clinical examination, pulmonary function test, and CT acquired during a routine follow-up

Related Conditions & MeSH terms

• Asthma
• COPD
• Cystic Fibrosis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Other:
• Observational study

Locations

Country	Name	City	State
France	Hopital Haut Leveque	Pessac

Sponsors (3)

Lead Sponsor	Collaborator
Hôpital Haut Lévêque	Collaborative NOVAA study group, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validity of automated measurement	Correlations and comparisons with other biomarker of the disease severity	From date of inclusion until the date of final quantification, assessed up to 12 months
Secondary	Correlation with pulmonary function test	Correlation of quantitative measurement with pulmonary function	From date of inclusion until the date of final quantification, assessed up to 12 months
Secondary	Longitudinal variation over time	Comparison of quantitative measurement at two time points	From date of inclusion until the date of final quantification, assessed up to 12 months
Secondary	Reproducibility	Evaluation of measurements when performed twice	From date of inclusion until the date of final quantification, assessed up to 12 months